Immunotherapy Basics in Melanoma

There are 3 major immunothearpy agents in the melanoma space. Hear one expert talk about them.

Mario Sznol, MD, professor of medicine and co-leader of cancer immunology at the Yale Cancer Center, discusses the most important immunotherapy agents in the field of melanoma.


Well at the moment there's really 2 major immunotherapy options in melanoma, maybe 3 if you count T-VEC, although I would say that's used relatively rarely in the clinic. The 2 most important drugs are anti-PD1, which are nivolumab (Opdivo) or pembrolizumab (Keytruda) and the other drug is anti-CTLA4, which is ipilimumab (Yervoy).

Anti-PD1 alone can give you long-term survival (rates) in the range of 40% to 45%. Anti-CTLA4 may add about another 7% to 10%, so that survival rate at 5 years. We tend to use either anti-PD1 alone or the combination of anti-PD1 and ipilimumab in the frontline setting in patients with metastatic melanoma.

Related Videos
Karyn Goodman
Reanne Booker on Factors to Consider When Discussing Palliative Radiation
Grace Choong
Mehra Details the Importance of PD-L1 Expression in HNSCC Treatment Selection
Ahulwalia on Targeting the Blood Brain Barrier With Novel Immunotherapies and Precision Oncology
Related Content
© 2023 MJH Life Sciences

All rights reserved.